Follow With Interest
More
1. Ophthalmic drugs are able to bind to melanin and accumulate in ocular tissues, causing ocular toxicity. On the other hand, the binding of ophthalmic drugs to melanin can also increase drug targeting for the delivery system of ophthalmic drugs. Therefore, studies evaluating the ability of new ophthalmic drugs to bind to melanin are essential in the development of new ophthalmic drugs.
Service | Melanin Binding |
Aims | To provide a scientific basis for new drug development in ophthalmology |
Testing system | Equilibrium dialysis |
Species | Melanin synthesized in vitro |
Testing concentrations | To be determined |
Incubation time | To be determined |
Analytical methods | LC-MS/MS |
Parameters | （% Bound = 100 × ([Donor]-[Receiver]) / [Donor]） |
2. In ophthalmic drug administration, the cornea acts as a barrier and can limit the absorption of topically administered drugs. Therefore, studies to evaluate the permeability of new drugs in the cornea are essential in the development of new ophthalmic drugs.
Service | Corneal cell permeability test |
Aims | To provide a scientific basis for new drug development in ophthalmology |
Testing system | Immortalized corneal epithelial cell |
Species | Human or animal |
Testing concentrations | To be determined |
Incubation time | To be determined |
Analytical methods | LC-MS/MS |
Parameters | Surface permeability (Papp) h/l ratio=P app（Test article）/P app（Prop） |